Cuál es el precio por Ceryvyn Therapeutics Ltd (OPT)

Precio por Ceryvyn Therapeutics Ltd (OPT) es de$0.00846342

Cuál es la capitalización de mercado por Ceryvyn Therapeutics Ltd (OPT)

Capitalización de mercado por Ceryvyn Therapeutics Ltd (OPT) es $11.27M

Ceryvyn Therapeutics Ltd (OPT) Desdoblamientos de Acciones

Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.

Año	Desdoblamiento	Multiplicador	Multiplicador acumulado
Not enough data for the provided dates.

Año

Desdoblamiento

Multiplicador

Multiplicador acumulado

Not enough data for the provided dates.

Empresa	Número de desdoblamientos de acciones	Multiplicador acumulado	País
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
CSL Limited CSL.AX	1	x3	AU
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR

Empresa

Número de desdoblamientos de acciones

Multiplicador acumulado

País